Uganda is among the 10 high-burden countries selected to benefit through the US President’s Emergency Plan for Aids Relief ...

From 2027, Indian generics companies and Hetero Labs Dr. Reddy's will supply lenacapavir, a twice-yearly injectable PrEP with ~96-100% efficacy, for US$40 (R698) per person per year across 120 low- ...

Press Release - The U.S. Department of State announced a life-saving development to bring U.S.-based Gilead Sciences' breakthrough drug lenacapavir to market in Uganda, one of just ten high-burden HIV ...

Two Indian generic drugmakers – Hetero and Dr Reddy’s – will be funded by the Gates Foundation and Unitaid, respectively, to ...